Arcus Biosciences Revenue 2011-2026 | RCUS

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Arcus Biosciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
247 M	258 M	117 M	112 M	383 M	78 M	15 M	8.35 M	1.41 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
383 M	1.41 M	136 M

Quarterly Revenue Arcus Biosciences

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
160 M	28 M	-	48 M	39 M	145 M	-	32 M	29 M	25 M	-	33 M	27 M	18 M	-	9.46 M	9.46 M	9.46 M	9.49 M	64.5 M	1.75 M	1.75 M	9.75 M	1.75 M	1.75 M	1.75 M	1.56 M	4.29 M	1.25 M	1.25 M	1.25 M	163 K	-141 K	-70 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
160 M	-141 K	23.8 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Apellis Pharmaceuticals APLS	1 B	$ 20.15	-2.68 %	$ 2.54 B	USA
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	912 K	$ 0.82	-3.48 %	$ 4.47 M	China
Axsome Therapeutics AXSM	638 M	$ 163.7	-1.61 %	$ 8.14 B	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
AbCellera Biologics ABCL	75.1 M	$ 3.72	-2.75 %	$ 1.11 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Burford Capital Limited BUR	330 M	$ 8.52	-2.46 %	$ 1.39 B	Britain
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Certara CERT	419 M	$ 7.16	1.49 %	$ 1.15 B	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	25.2 M	$ 25.91	-3.56 %	$ 694 M	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	59.3 M	$ 0.99	-3.28 %	$ 72.7 M	USA
Catalyst Pharmaceuticals CPRX	589 M	$ 24.0	0.5 %	$ 2.93 B	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	156 M	$ 3.19	-4.64 %	$ 1.14 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Agios Pharmaceuticals AGIO	54 M	$ 28.78	-1.44 %	$ 1.67 B	USA
Champions Oncology CSBR	56.9 M	$ 6.0	-1.15 %	$ 82 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Завод ДИОД DIOD	517 M	-	-	-	Russia
Фармсинтез LIFE	372 M	-	-	-	Russia
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
Cellectis S.A. CLLS	41.5 M	$ 3.67	-3.42 %	$ 116 M	France
Alector ALEC	21 M	$ 2.11	-4.75 %	$ 217 M	USA
KalVista Pharmaceuticals KALV	50 M	$ 15.68	-2.4 %	$ 779 M	Britain
Altimmune ALT	20 K	$ 4.17	0.24 %	$ 296 M	USA
Teligent, Inc. TLGT	45.3 M	-	-13.85 %	$ 16.1 M	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Viela Bio, Inc. VIE	11.7 M	-	-	$ 2.91 B	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	214 M	$ 14.27	2.44 %	$ 5.92 B	Irlanda